ArticleJournal of Korean medical science2024
Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database.
Article in Journal of Korean medical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Multimodality staging of renal cell carcinoma-pearls & pitfalls.Abdominal radiology (New York) · 2026Review
- Imaging response assessment in metastatic renal cell carcinoma: a radiologist's guide to contemporary therapeutic strategies.Abdominal radiology (New York) · 2026Review
- Metastatic Patterns and Adverse Histopathologic Features in Advanced Renal Cell Carcinoma: A Five-Year Single-Center Retrospective Pathology Study.Medicina (Kaunas, Lithuania) · 2026Article
- Metachronous metastasis of renal cell carcinoma to the contralateral ureter 8 years after nephrectomy presenting as hydronephrosis.Urology case reports · 2026Article
- Stereotactic ablative radiotherapy: an effective alternative for pancreatic metastases originating from renal cell carcinoma-experience from two European institutions.Clinical & experimental metastasis · 2026Article
- Clear Cell Renal Cell Carcinoma with Synchronous Bladder Metastasis: Diagnostic, Surgical, and Pathological Insights from a Rare Presentation.Journal of clinical medicine · 2026Article
- The C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index as an Independent Predictor of Progression and Survival in Metastatic Renal Cell Carcinoma.Journal of clinical medicine · 2026Article
- Article
- First-Line Treatment Strategies in IMDC Favourable-Risk Metastatic Clear Cell Renal Cell Carcinoma.Oncology research · 2026Review
- One size does not fit all: rethinking IO-TKI use in favorable-risk metastatic ccRCC.Frontiers in oncology · 2026Article
- Clear Cell Renal Cell Carcinoma: Rare and Atypical Metastatic Localizations-A Case Series.Case reports in urology · 2026Article
- Predicting distant metastasis in early-onset kidney cancer using machine learning: a SEER database study with external validation.Clinical and experimental medicine · 2025Article
- Tumor necrosis-informed prognostic nomogram for clear cell renal cell carcinoma model development and clinical validation.BMC urology · 2025Article
- Double Aortic Contour in Chest Radiography.Cureus · 2025Article
- Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types.Current oncology (Toronto, Ont.) · 2025Article
- Clear cell renal carcinoma metastasis to the thyroid gland combined with papillary thyroid carcinoma - a case report.Frontiers in oncology · 2025Article
- Giant thyroid metastasis originating from renal carcinoma: a case report.Frontiers in oncology · 2025Article
- Renal metastasis of adenocarcinoma of the gastrointestinal tract with unknown primary site: a case report and review of the literature.Therapeutic advances in urologyArticle
- Prediction of Distant Metastasis in Renal Cell Carcinoma Using Machine Learning Algorithms: A Multicenter Cohort Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn patients with metastatic renal cell carcinoma (mRCC), sites of metastatic involvement have been reported to be associated with a difference in survival. However, the frequency and survival according to different sites of metastases in Korean patients with mRCC remain unclear. Therefore, this study aimed to assess the frequency of metastatic site involvement and the association between sites of metastatic involvement and survival in Korean patients with mRCC.
methodsThis retrospective study used the multicenter cohort of the Korean Renal Cancer Study Group mRCC database to identify patients who started targeted therapy between December 2005 and March 2018. Data on the frequency of metastatic organ involvement at the time of mRCC diagnosis and oncologic outcomes according to different sites of metastasis were analyzed.
resultsA total of 1,761 patients were eligible for analysis. Of the 1,761 patients, 1,564 (88.8%) had clear cell RCC, and 1,040 (59.1%) had synchronous metastasis. The median number of metastasis sites was 2 (interquartile range [IQR], 1-6). The median age at the initiation of systemic therapy was 60 years (IQR, 29-88), 1,380 (78.4%) were men, and 1,341 (76.1%) underwent nephrectomy. Based on the International Metastatic Renal Cell Carcinoma Database Consortium model, patients were stratified into favorable-, intermediate-, and poor-risk groups with 359 (20.4%), 1,092 (62.0%), and 310 (17.6%) patients, respectively. The lung (70.9%), lymph nodes (37.9%), bone (30.7%), liver (12.7%), adrenal gland (9.8%), and brain (8.2%) were the most common sites of metastasis, followed by the pancreas, pleura, peritoneum, spleen, thyroid, and bowel. Among the most common sites of metastasis (> 5%), the median cancer-specific survival (CSS) ranged from 13.9 (liver) to 29.1 months (lung). An association was observed between liver, bone, and pleural metastases and the shortest median CSS (< 19 months).
conclusionIn Korean patients with mRCC, metastases to the lung, lymph nodes, bone, liver, adrenal gland, and brain were more frequent than those to other organs. Metastases to the liver, bone, and pleura were associated with poor CSS. The findings of this study may be valuable for patient counseling and guiding future study designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.